US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Iambic Therapeutics / Equity Capital Markets

<ul>
<li>AI is the differentiator: Iambic integrates proprietary AI models, automated laboratories and experimental feedback into a continuous drug-discovery platform.</li>
<li>Credible industry relationships: Collaborations involving AbbVie, Takeda, Lundbeck, NVIDIA and other notable companies strengthen the platform’s commercial and scientific credibility.</li>
<li>Market execution remains uncertain: The AI narrative could attract investor attention, but recent biotech IPO weakness raises the bar for a strong debut.</li>
</ul>


AI is the differentiator: Iambic integrates proprietary AI models, automated laboratories and experimental feedback into a continuous drug-discovery platform.
Credible industry relationships: Collaborations involving AbbVie, Takeda, Lundbeck, NVIDIA and other notable companies strengthen the platform’s commercial and scientific credibility.
Market execution remains uncertain: The AI narrative could attract investor attention, but recent biotech IPO weakness raises the bar for a strong debut.


Iambic Therapeutics Inc. (IAM): Bringing an AI Twist to the Biotech IPO Market

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>✓ IPO Prophet Rating: 7.83/10 🏦 Deal Quality &amp; Underwriters: 8.35/10 Iambic Therapeutics is offering 9.38 million all-primary shares at $15.00–$17.00, representing approximately $150 million at the midpoint and an implied market capitalization of roughly $758 million.</li><li>The Nasdaq transaction is expected to price October 15 under the ticker IAM.</li><li>J.P. Morgan, Jefferies, BofA Securities and Citigroup provide a strong healthcare-focused underwriting syndicate capable of reaching both specialist biotechnology investors and broader institutions. </li></ul>

✓ IPO Prophet Rating: 7.83/10 🏦 Deal Quality &amp; Underwriters: 8.35/10 Iambic Therapeutics is offering 9.38 million all-primary shares at $15.00–$17.00, representing approximately $150 million at the midpoint and an implied market capitalization of roughly $758 million.The Nasdaq transaction is expected to price October 15 under the ticker IAM.J.P. Morgan, Jefferies, BofA Securities and Citigroup provide a strong healthcare-focused underwriting syndicate capable of reaching both specialist biotechnology investors and broader institutions. 

<ul>
<li>Iambic Therapeutics (IAM) , a San Diego-based biotechnology company combining artificial intelligence with automated laboratory research, is preparing to offer 9.375 million shares on the Nasdaq Global Select Market at $15–$17 per share .</li>
<li>At the $16 midpoint , the offering would raise $150 million in gross proceeds and imply a post-offering market capitalization of approximately $758.4 million .</li>
<li>J.P. Morgan, Jefferies, BofA Securities, and Citigroup are the joint book-running managers. The preliminary prospectus does not specify a final pricing or trading date.</li>
</ul>


Iambic Therapeutics (IAM) , a San Diego-based biotechnology company combining artificial intelligence with automated laboratory research, is preparing to offer 9.375 million shares on the Nasdaq Global Select Market at $15–$17 per share .
At the $16 midpoint , the offering would raise $150 million in gross proceeds and imply a post-offering market capitalization of approximately $758.4 million .
J.P. Morgan, Jefferies, BofA Securities, and Citigroup are the joint book-running managers. The preliminary prospectus does not specify a final pricing or trading date.


Iambic Therapeutics (IAM) Eyes $150 Million IPO to Advance AI-Designed Cancer Therapies

<ul>
<li>AI Meets Biotech: Iambic combines proprietary AI with automated chemistry and biology to accelerate drug discovery through a continuous design–make–test platform.</li>
<li>Strong Strategic Backing: ARK Invest and Duquesne have expressed interest in purchasing up to $60 million, providing a meaningful anchor for the IPO.</li>
<li>Partnership Validation: Collaborations with AbbVie, Takeda, Lundbeck and others provide funding, data, expertise and external validation of Iambic’s technology.</li>
</ul>


AI Meets Biotech: Iambic combines proprietary AI with automated chemistry and biology to accelerate drug discovery through a continuous design–make–test platform.
Strong Strategic Backing: ARK Invest and Duquesne have expressed interest in purchasing up to $60 million, providing a meaningful anchor for the IPO.
Partnership Validation: Collaborations with AbbVie, Takeda, Lundbeck and others provide funding, data, expertise and external validation of Iambic’s technology.


Iambic Therapeutics Inc. (IAM): Ark Invest Backs AI-Driven Drug Platform, Sets Terms for IPO

Healthcare Analyst

Wilfred Yuen

<ul>
<li>Founded in 2019 and backed by NVIDIA, Iambic is a technology and clinical-stage biotech company. S1 was filed on 21 September.</li>
<li>Iambic's value creation hinges on 1) its molecular superintelligence platform (flagship AI models Enchant/NeuralPLexer), 2) pipeline: partnered/wholly-owned programs including clinical-stage IAM1363 (Type2 HER2 inhibitor), 3) a growing roster of partnerships</li>
<li>1H26 collaboration revenue and net loss amounted to US$12.8m (vs. US$3.9m in 1H25) and US$50.2m, respectively. See inside for more on Iambic AI models and IAM1363 clinical data</li>
</ul>


Founded in 2019 and backed by NVIDIA, Iambic is a technology and clinical-stage biotech company. S1 was filed on 21 September.
Iambic's value creation hinges on 1) its molecular superintelligence platform (flagship AI models Enchant/NeuralPLexer), 2) pipeline: partnered/wholly-owned programs including clinical-stage IAM1363 (Type2 HER2 inhibitor), 3) a growing roster of partnerships
1H26 collaboration revenue and net loss amounted to US$12.8m (vs. US$3.9m in 1H25) and US$50.2m, respectively. See inside for more on Iambic AI models and IAM1363 clinical data


Iambic Tx IPO First-Read: AI Models Enchant/NeuralPLexer, IAM1363 (Type II HER2i), Partnerships

United States

Iambic Therapeutics, Inc. is a technology and clinical-stage life sciences company, The Company focuses on developing, discovering, and advancement of new medicines to address unmet patient need through its molecular superintelligence platform. Iambic Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Iambic Therapeutics (IAM US)

Iambic Therapeutics Inc. (IAM): Bringing an AI Twist to the Biotech IPO Market

Iambic Therapeutics pairs AI-driven drug discovery with automated labs and a clinical-stage oncology pipeline. Strong reported demand and high...

IPO Boutique

IPO Rating: Iambic Therapeutics, Inc.

✓ IPO Prophet Rating: 7.83/10 🏦 Deal Quality & Underwriters: 8.35/10 Iambic Therapeutics is offering 9.38 million all-primary shares at...

IPO Prophet

Iambic Therapeutics (IAM) Eyes $150 Million IPO to Advance AI-Designed Cancer Therapies

Iambic Therapeutics (IAM) , a San Diego-based biotechnology company combining artificial intelligence with automated laboratory research, is...

IPO Prophet

Iambic Therapeutics Inc. (IAM): Ark Invest Backs AI-Driven Drug Platform, Sets Terms for IPO

Iambic brings AI to drug discovery, backed by ARK and Duquesne and partnerships with pharma leaders, offering investors exposure to the...

IPO Boutique

Iambic Tx IPO First-Read: AI Models Enchant/NeuralPLexer, IAM1363 (Type II HER2i), Partnerships

NVIDIA-backed AI drug discovery Iambic Tx filed S1 last week. Our first-take: 1) its flagship AI models Enchant/NeuralPLexer, 2) clinical-stage...

Wilfred Yuen

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)